Twitter

Tirzepatide now licensed by the EMA 🇪🇺 for the management of #Type2Diabetes

@kamleshkhunti...

👉although due to supply chain issues no stock in 🇪🇺 for probably about a year

👉reminder of the class leading (incretin)
⤵️HbA1c
⤵️weight
👇👇👇

New—FDA approves #teplizumab: a milestone in type 1 #diabetes ...https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00351-5/fulltext #T1D
#FREE to read with registration (also FREE)

Donderdag 8 december: Obesitas Jaaroverzicht 2022

Inschrijven voor het Obesitas Jaaroverzicht kan ...via de onderstaande link.

Aanvullende informatie over het programma volgt.

Organisatie: @NL_OBPL

https://doc.webinargeek.com/obesitas-jaaroverzicht-2022

Impressive benefits for empagliflozin therapy in people with #CKD ...https://www.nejm.org/doi/full/10.1056/NEJMoa2204233?query=featured_home

Joline Beulens presents the recent results from the @SupremeNudge study at the #ADDRM: how does ...nudging in supermarkets affect healthy eating habits?